Guggenheim reissued their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK – Free Report) in a research note released on Tuesday,Benzinga reports. They currently have a $60.00 price target on the stock.
A number of other analysts have also commented on the company. Canaccord Genuity Group dropped their price target on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a research note on Tuesday. The Goldman Sachs Group began coverage on shares of Stoke Therapeutics in a research report on Monday, July 13th. They set a “buy” rating and a $44.00 price objective on the stock. Chardan Capital restated a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a report on Tuesday. Wedbush raised their target price on shares of Stoke Therapeutics from $38.00 to $40.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, BTIG Research reaffirmed a “buy” rating and set a $39.00 target price on shares of Stoke Therapeutics in a research note on Monday, May 11th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Stoke Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $43.00.
Read Our Latest Stock Analysis on STOK
Stoke Therapeutics Price Performance
Stoke Therapeutics (NASDAQ:STOK – Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.13). The business had revenue of $9.32 million during the quarter, compared to analysts’ expectations of $4.89 million. Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%. As a group, sell-side analysts expect that Stoke Therapeutics will post -3.41 EPS for the current fiscal year.
Insider Transactions at Stoke Therapeutics
In related news, insider Barry Ticho sold 7,176 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $29.04, for a total transaction of $208,391.04. Following the sale, the insider owned 20,422 shares of the company’s stock, valued at $593,054.88. The trade was a 26.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Jonathan Allan sold 1,457 shares of the business’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $29.95, for a total transaction of $43,637.15. Following the sale, the general counsel directly owned 18,086 shares in the company, valued at $541,675.70. The trade was a 7.46% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 10,428 shares of company stock worth $306,919 over the last ninety days. Insiders own 9.60% of the company’s stock.
Hedge Funds Weigh In On Stoke Therapeutics
Large investors have recently made changes to their positions in the business. Kestra Advisory Services LLC bought a new stake in shares of Stoke Therapeutics in the 4th quarter worth approximately $26,000. KBC Group NV bought a new position in Stoke Therapeutics during the 1st quarter valued at approximately $36,000. Harbour Investments Inc. raised its stake in Stoke Therapeutics by 312.9% during the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after buying an additional 898 shares during the last quarter. Western Wealth Management LLC purchased a new position in Stoke Therapeutics during the first quarter valued at $55,000. Finally, EverSource Wealth Advisors LLC boosted its holdings in Stoke Therapeutics by 195.3% in the first quarter. EverSource Wealth Advisors LLC now owns 1,837 shares of the company’s stock worth $60,000 after acquiring an additional 1,215 shares in the last quarter.
Stoke Therapeutics News Roundup
Here are the key news stories impacting Stoke Therapeutics this week:
- Positive Sentiment: Wedbush raised its price target to $40 and maintained an “outperform” rating, while Chardan Capital reiterated “buy” with a $35 target. Canaccord retained a “buy” rating despite lowering its target to $58. The broader analyst consensus remains “Moderate Buy,” with an average target of $43. Wedbush price-target update
- Positive Sentiment: Investors continue to focus on Stoke’s pipeline. Management plans to submit a rolling NDA for zorevunersen in the first quarter of 2027 for SCN1A-related Dravet syndrome, while continuing development of STK-002. Approximately $420 million in cash could support these programs and potential launch preparations. Pipeline and NDA outlook
- Neutral Sentiment: Stoke is scheduled to present at the Canaccord Genuity 46th Annual Growth Conference, giving management an opportunity to provide updates on its clinical and regulatory plans. Conference presentation announcement
- Negative Sentiment: HC Wainwright cut its EPS forecasts across 2026–2028: FY2026 to a loss of $3.35 per share from $3.09, FY2027 to a loss of $2.55 from $2.05, and FY2028 to a loss of $1.78 from $0.67. It also lowered quarterly estimates to losses of $0.81 per share. These revisions point to slower progress toward profitability. HC Wainwright earnings estimates
- Negative Sentiment: Stoke’s second-quarter loss of $0.93 per share exceeded the expected loss of $0.80, although revenue of approximately $9.33 million surpassed estimates. The company remains deeply unprofitable, increasing investor sensitivity to cash use and development execution. Second-quarter earnings summary
- Negative Sentiment: Director Barry Ticho sold 7,176 shares for approximately $208,000, reducing his stake by 26%. The sale was conducted under a pre-arranged Rule 10b5-1 plan, which limits its significance but may still weigh modestly on sentiment. SEC insider-sale filing
Stoke Therapeutics Company Profile
Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.
The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.
Featured Stories
- Five stocks we like better than Stoke Therapeutics
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
